Jonathan Hunt detailed the investment strategy of Syngene International, facing revenue growth challenges due to US biotech funding delays. Expecting high single to low double digits growth for FY25, with ongoing developments in various company facilities. Hunt says: "We deployed $55 million last year. Next year, we will be a little bit ahead of that."
Visa, Mastercard Agree to Lower Swipe Fees The card networks would cap credit-card interchange fees for five years as part of a settlement with merchants.
Canada s Poor Productivity Has.
The Crypto Reboot That Wasn t: Why FTX 2.0 Floundered Creditors say FTX s post-chapter 11 management team missed an opportunity to create a valuable business from the ashes of the.